Skip to content

Section archive

Page 4 of 5

Prostate Cancer

A phase 2 trial of the Prostvac-VF vaccine in men with symptomatic castration-resistant metastatic prostate cancer reported a 44 percent lower death rate over three years, with 30 percent alive versus 17 percent of controls. One catch: vaccinated men averaged about four years younger.

1 min read

78 stories